Broth microdilution

Worldwide Antimicrobial Susceptibility Test Industry to 2027 - Drivers, Restraints, Opportunities and Threats

Retrieved on: 
Thursday, July 2, 2020

DUBLIN, July 2, 2020 /PRNewswire/ -- The "Antimicrobial Susceptibility Test - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 2, 2020 /PRNewswire/ -- The "Antimicrobial Susceptibility Test - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Antimicrobial Susceptibility Test market accounted for $2.79 billion in 2019 and is expected to reach $4.98 billion by 2027 growing at a CAGR of 7.5% during the forecast period.
  • To examine the antimicrobial susceptibility, the most widely used testing methods are broth microdilution or rapid automated instrument methods.
  • The rising prevalence of antimicrobial resistance in North America is another key factor supporting the expansion of this regional segment in the global antimicrobial susceptibility testing market.

Global Antimicrobial Susceptibility Test Market Outlook (2019 to 2027) - Featuring Biotron Healthcare, Conda & Creative Diagnostics Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, June 26, 2020

The "Antimicrobial Susceptibility Test - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antimicrobial Susceptibility Test - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Antimicrobial Susceptibility Test market accounted for $2.79 billion in 2019 and is expected to reach $4.98 billion by 2027 growing at a CAGR of 7.5% during the forecast period.
  • To examine the antimicrobial susceptibility, the most widely used testing methods are broth microdilution or rapid automated instrument methods.
  • The rising prevalence of antimicrobial resistance in North America is another key factor supporting the expansion of this regional segment in the global antimicrobial susceptibility testing market.

OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing Based Antibiotic Susceptibility Testing in Multi-Center Study

Retrieved on: 
Thursday, April 16, 2020

1) reports on a study evaluating the performance of pathogen identification and antibiotic susceptibility testing based on whole genome DNA sequencing (WGS) using Ares Genetics AI-powered cloud-based bioinformatics platform ares-genetics.cloud and its underlying reference database, ARESdb.

Key Points: 
  • 1) reports on a study evaluating the performance of pathogen identification and antibiotic susceptibility testing based on whole genome DNA sequencing (WGS) using Ares Genetics AI-powered cloud-based bioinformatics platform ares-genetics.cloud and its underlying reference database, ARESdb.
  • WGS-predicted susceptibility to antibiotics showed 89% categorical agreement with the current reference method of broth microdilution susceptibility testing across a total of 129 pathogen-drug pairs analyzed.
  • Dr. Andreas Posch, CEO of Ares Genetics and senior author of the study, commented, This multi-center study clearly demonstrates the feasibility and potential of next-generation sequencing based antibiotic susceptibility testing using our AI-powered cloud platform.
  • The Review on Antimicrobial Resistance, chaired by Jim ONeill, Wellcome Trust & HM Gove
    For further information, please register on the Ares Genetics cloud platform:

Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting

Retrieved on: 
Thursday, May 2, 2019

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 22nd Annual MAD-ID (Making a Difference in Infectious Diseases) Meeting, taking place May 8-11, 2019 in Orlando, Fla.

Key Points: 
  • Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 22nd Annual MAD-ID (Making a Difference in Infectious Diseases) Meeting, taking place May 8-11, 2019 in Orlando, Fla.
  • The details for the data presentations at MAD-ID are as follows:
    Date and time: Thursday, May 9 from 5:00 6:30 p.m.
  • ET
    Poster title: Multi-Site Evaluation of Eravacycline MIC Test Strip Compared to Broth Microdilution for Enterobacteriaceae, S. aureus and Enterococcus spp.
  • To report SUSPECTED ADVERSE REACTIONS, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .